Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure

The purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels and insulin resistance in patients with chronic heart failure.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Stable Heart Failure Cardiovascular Diseases Fibrosis Heart Diseases Heart Failure Pathologic Processes Pathological Conditions, Signs and Symptoms

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

About this study

Myocardial fibrosis is observed in failing hearts. MMPs are considered markers of fibrosis. Recently, circulating MMPs can be measured and are elevated in patients with chronic heart failure (CHF). It has been reported that spironolactone improves myocardial fibrosis in CHF animal models. Therefore, the purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels in patients with chronic heart failure.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

chronic stable heart failure

Treatment and study plan

spironolactone + furosemide

Drug

spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16 weeks

Primary outcomes

MMP levels

Time frame: 16 weeks

Sponsors and collaborators

Lead sponsor

Tottori University Hospital

Other

Registry information

Official study title

Effects of Spironolactone on Circulating MMPs in Patients With Chronic Heart Failure

Important dates

Study start: 2004
Study completion: 2005
First posted: Apr 22, 2008
Registry last updated: Apr 22, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed